Evaluation of Molecular Markers in Adrenal Tumors
|ClinicalTrials.gov Identifier: NCT01348698|
Recruitment Status : Terminated
First Posted : May 5, 2011
Last Update Posted : February 14, 2018
- Tumors of the adrenal gland are common. Most of them are not cancerous. However, there are no tests that can accurately tell which adrenal tumors are cancerous and which are not. The only way to tell is to remove the tumor with surgery and then examine it. Researchers have been using new methods to study samples of adrenal tissue. These methods may help identify whether the cells are or may become cancerous without an operation. This information will help doctors determine which tumors will need to be removed.
- To collect adrenal tumor tissue biopsy samples in order to study and evaluate new methods that may help identify cancerous or precancerous cells.
- Individuals at least 18 years of age who have an adrenal tumor that may or may not be cancerous.
- Participants will be screened with a physical examination, medical history, blood and urine tests, and imaging studies.
- Participants will be examined to determine whether they have a specific type of adrenal tumor
- Participants whose tumor does not secrete hormones will have a tumor biopsy to collect tissue for study.
- Participants who have a large tumor or one that secretes hormones will have standard surgery to remove the tumor. Tissue will be collected for study.
- Researchers will examine the collected tissue. They will try to determine whether the cells are cancerous or may become cancerous.
- Participants will be asked to return to the National Institutes of Health Clinical Center every year for about 5 years. During these visits they will have imaging studies, lab tests, and a physical examination.
|Condition or disease|
|Adrenal Gland Neoplasms|
- Adrenal neoplasms are common and are incidentally discovered in 4-10% of abdominal imaging studies.
- The majority of adrenal incidentalomas are cortical adenoma.
- Many patients with nonfunctioning adrenal incidentalomas undergo adrenalectomy to exclude a cancer diagnosis.
- There are no reliable clinical, radiographic or laboratory studies that accurately distinguish between localized benign and malignant adrenal neoplasm.
- This protocol is designed to determine the feasibility and accuracy of using novel molecular markers of malignant adrenal neoplasm in fine needle aspiration (FNA) biopsy and surgically resected samples.
- To evaluate the feasibility of molecular testing in adrenal neoplasm FNA biopsy samples.
- To determine the accuracy of novel diagnostic molecular markers in clinical adrenal FNA biopsy and surgically resected samples.
- To analyze the gene expression level relative to disease-free survival and overall survival in patients with adrenocortical carcinoma
- An individual with an adrenal neoplasm greater than 2cm in size
- Age greater than or equal to 18 years
- Adults must be able to understand and sign the informed consent document
- Prospective observational study.
- Demographic, clinical, laboratory and pathologic data will be collected for each patient participant. Data will be securely stored in a computerized database.
- Patients will have biochemical testing to determine if their adrenal neoplasm is functioning or nonfunctioning.
- After their initial on-study evaluation, patients who are found to have a nonfunctioning adrenal tumor with a low risk of malignancy will be re-screened every year for 5 years with non-invasive imaging studies.
- Treatment of patients with an adrenal neoplasm will be performed based on standard clinical practice.
- Projected accrual will be 50 patients per year for a total of 10 years. Thus, we anticipate accruing 500 patients on this protocol.
|Study Type :||Observational|
|Actual Enrollment :||74 participants|
|Official Title:||Evaluation of Diagnostic and Prognostic Molecular Markers in Adrenal Neoplasm|
|Study Start Date :||May 4, 2011|
|Study Completion Date :||January 12, 2018|
- Determine feasibility of molecular testin in adrenal neoplasm FNA samples. [ Time Frame: 10 Years ]
- To analyze the gene expression level relative to disease-free survivaland overall survival in patients with adrenocortical carcinoma [ Time Frame: 10 years ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01348698
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Electron Kebebew, M.D.||National Cancer Institute (NCI)|